Main Menu

Publications Highlights View all by category

Types of Publications


Journal Articles

Balyasnikova, S., Vuong, T., Wale, A., Chong, I., Rutten, H. & Brown, G. (2018). Session 3: Boosting primary and recurrent rectal cancer: how far can we push the radiotherapy envelope?. Colorectal disease, Vol.20, pp. 88-91.

Patel, A., Chang, G., Wale, A., Chong, I., Rutten, H., Nicholls, J., Hawkins, M., Steele, R.J., Marks, J. & Brown, G., et al. (2018). Session 3: Intra-operative radiotherapy - creating new surgical boundaries. Colorectal disease, Vol.20, pp. 65-75.

Petty, R.D., Dahle-Smith, A., Stevenson, D.A., Osborne, A., Massie, D., Clark, C., Murray, G.I., Dutton, S.J., Roberts, C., Chong, I.Y., et al. (2017). Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer. J clin oncol, Vol.35 (20), pp. 2279-2287.  show abstract

Battersby, N.J., Dattani, M., Rao, S., Cunningham, D., Tait, D., Adams, R., Moran, B.J., Khakoo, S., Tekkis, P., Rasheed, S., et al. (2017). A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial. Trials, Vol.18 (1).

Campbell, J., Ryan, C.J., Brough, R., Bajrami, I., Pemberton, H.N., Chong, I.Y., Costa-Cabral, S., Frankum, J., Gulati, A., Holme, H., et al. (2016). Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines. Cell reports, Vol.14 (10), pp. 2490-2501.

Wetterskog, D., Shiu, K.-., Chong, I., Meijer, T., Mackay, A., Lambros, M., Cunningham, D., Reis-Filho, J.S., Lord, C.J. & Ashworth, A., et al. (2014). Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers. Oncogene, Vol.33 (8), pp. 966-976.

Hoskin, P.J., Rojas, A.M., Peiris, S.N., Mullassery, V. & Chong, I.Y. (2014). Pre-treatment Haemoglobin and Peripheral Blood Lymphocyte Count as Independent Predictors of Outcome in Carcinoma of Cervix. Clinical oncology, Vol.26 (4), pp. 179-184.

Chong, I.Y., Cunningham, D., Barber, L.J., Campbell, J., Chen, L., Kozarewa, I., Fenwick, K., Assiotis, I., Guettler, S., Garcia-Murillas, I., et al. (2013). The genomic landscape of oesophagogastric junctional adenocarcinoma. The journal of pathology, Vol.231 (3), pp. 301-310.

Chong, I., Hawkins, M., Hansen, V., Thomas, K., McNair, H., O’Neill, B., Aitken, A. & Tait, D. (2011). Quantification of Organ Motion During Chemoradiotherapy of Rectal Cancer Using Cone-Beam Computed Tomography. International journal of radiation oncology*biology*physics, Vol.81 (4), pp. e431-e438.

Wetterskog, D., Shiu, K.-., Chong, I., Meijer, T., Natrajan, R., Lord, C.J., Ashworth, A. & Reis-Filho, J.S. (2011). Abstract 4987: Identification of novel genes and pathways involved in resistance to HER2-targeting agents in breast cancer. Cellular and molecular biology, .

Chong, I., Wetterskog, D., Shiu, K.-., Meijer, T., Natrajan, R., Maryou, L., Reis-Filho, J., Lord, L.J., David, C. & Ashworth, A., et al. (2011). Abstract 3039: Identification of a novel biomarker of resistance to lapatinib common to both breast and oesophagogastric cancer. Cellular and molecular biology, .

Cunningham, D. & Chong, I. (2010). Optimal treatment of metastatic pancreatic cancer. Gut, Vol.59 (11), pp. 1454-1455.

Chong, I.Y., Brown, G., Heald, R.J., Thomas, K., Chau, I., Wotherspoon, A. & Tait, D.M. (2010). A multicenter phase II clinical study evaluating the deferral of rectal surgery following a continued response to preoperative chemoradiotherapy (CRT). Journal of clinical oncology, Vol.28 (15_suppl), pp. TPS191-TPS191.

Chong, I.Y., Okines, A.F., Tait, D.M., Hawkins, M., Cunningham, D., Saffery, C., Thomas, K. & Chau, I. (2010). A multicenter randomized phase II study of UFT/leucovorin and radiotherapy (RT) with or without cetuximab following induction gemcitabine plus capecitabine (GEM-CAP) in locally advanced pancreatic cancer (LAPC). Journal of clinical oncology, Vol.28 (15_suppl), pp. TPS221-TPS221.

Chong, I. & Hoskin, P.J. (2008). Vaginal vault brachytherapy as sole postoperative treatment for low-risk endometrial cancer. Brachytherapy, Vol.7 (2), pp. 195-199.

Chong, I. Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer. Gut, .

Bajrami, I., Marlow, R., van de Ven, M., Brough, R., Pemberton, H., Frankum, J., Song, F., Raquif, R., Konde, A., Krastev, D., et al. E-cadherin/ROS1 inhibitor synthetic lethality in breast cancer. Cancer discovery, .


Conferences

Chong, I., Cunningham, D., Campbell, J., Bajrami, I., Brough, R., Frankum, J., Lord, C. & Ashworth, A. (2014). PD-0017 * DRUGGABLE GENETIC DEPENDENCIES FOR MOLECULARLY DEFINED SUBGROUPS OF OESOPHAGEAL CANCER IDENTIFIED FROM HIGH-THROUGHPUT FUNCTIONAL PROFILING, Annals of Oncology, Vol.25 (suppl 2), p.ii11.

Chong, I.Y., Cunningham, D., Elliott, R., Konde, A., Campbell, J., Menon, M., Bowers, L., Daley, F., Lord, C.J. & Ashworth, A., et al. (2014). Candidate drug therapies for molecularly defined subgroups of esophageal cancer identified from high-throughput drug screening., Journal of Clinical Oncology, Vol.32 (15_suppl), p.4039.

Chong, I.Y., Hooper, S.D., Cunningham, D., Elliott, R., Chen, L., Campbell, J., Bajrami, I., Kozarewa, I., Wetterskog, D., Wilkerson, P.M., et al. (2013). Association of high-throughput RNAi and drug screening with candidate novel therapeutic targets in esophageal carcinoma., Journal of Clinical Oncology, Vol.31 (4_suppl), p.31.

In this section

Publications